Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |Streptavidin（SA） Hot |Claudin 18.2 |Cadherin-17 
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF R2

VEGF R2

Brief Information

Name:Vascular endothelial growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,VEGFR2,KDR,Vascular endothelial growth factor receptor 2,Fetal liver kinase 1,Kinase insert domain receptor,Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase),Protein-Tyrosine Kinase Receptor Flk-1,FLK1,Tyrosine Kinase Growth Factor Receptor,Fetal Liver Kinase-1,Soluble VEGFR2,CD309 Antigen,EC 2.7.10.1,VEGFR-2,CD309,VEGFR,FLK-1,Vascular Endothelial Growth Factor Receptor-2
Number of Launched Drugs:17
Number of Drugs in Clinical Trials:52
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VE2-HA224 Human APC-Labeled Human VEGF R2 / KDR Protein, His Tag (Site-specific conjugation)
VE2-HA224-structure
KDR-HP227 Human PE-Labeled Human VEGF R2 / KDR Protein, His Tag (Site-specific conjugation)
KDR-HP227-structure
CHEK-ATF044 Human VEGFR2 (Luc) HEK293 Reporter Cell
VE2-H5255 Human Human VEGF R2 / KDR Protein, Fc Tag (MALS verified)
VE2-H5255-structure
VE2-H5255-sds
VE2-HF254 Human FITC-Labeled Human VEGF R2 / KDR Protein, His Tag
VE2-HF254-structure
VE2-HF254-sds
VE2-M5258 Mouse Mouse VEGF R2 / KDR Protein, Mouse IgG2a Fc Tag, low endotoxin
VE2-M5258-structure
VE2-M5258-sds
KDR-H82E5 Human Biotinylated Human VEGF R2 / KDR Protein, Avitag™,His Tag
KDR-H82E5-structure
KDR-H82E5-sds
VE2-C52H3 Rhesus macaque Rhesus macaque VEGF R2 / KDR Protein, His Tag
VE2-C52H3-structure
VE2-C52H3-sds
KDR-H5280 Human Human VEGF R2 / KDR Protein, Twin-Strep Tag (MALS verified)
KDR-H5280-structure
KDR-H5280-sds
KDR-H5227 Human Human VEGF R2 / KDR Protein, His Tag (MALS verified)
KDR-H5227-structure
KDR-H5227-sds
ACRO Quality

Part of Bioactivity data

VE2-HA224-Cell-based assay
VEGF R2 FACS

5e5 of anti-VEGF R2 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human VEGF R2 Protein, His Tag (Cat. No. VE2-HA224) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

Protocol
KDR-HP227-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-VEGFR2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human VEGF R2, His Tag (Cat. No. KDR-HP227) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

Protocol
VE2-M5258-BLI
VEGF R2 BLI

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R2 Protein, Mouse IgG2a Fc Tag (Cat. No. VE2-M5258) with an affinity constant of 1.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
KDR-H82E5-BLI
VEGF R2 BLI

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Synonym Name

KDR,CD309,FLK1,VEGFR,VEGFR2

Background

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and  is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

Related Molecule

VEGF165 VEGF121

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt EU Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef EU systemic sclerosis-associated interstitial lung disease Boehringer Ingelheim International Gmbh 2014-10-15 Gliosarcoma; Breast Neoplasms; Sarcoma; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Genital Neoplasms, Female; Silicosis; Prostatic Neoplasms; Carcinoma, Squamous Cell; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Ovarian Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoid Tumor; Endometrial Stromal Tumors; Carcinoma, Renal Cell; Radiation Pneumonitis; Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours; Scleroderma, Systemic; Glioblastoma; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis; Oligodendroglioma Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Carcinoma, Renal Cell Merck Sharp & Dohme Corp 2015-02-13 Liver Diseases; Paraganglioma; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Osteosarcoma; Cholangiocarcinoma; Breast Neoplasms; Solid tumours; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Kidney Diseases; Neoplasms; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Pheochromocytoma; Renal Insufficiency; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms Details
Apatinib Mesylate YN-968D1 Approved Advenchen Laboratories Llc 艾坦, Aitan Mainland China Stomach Neoplasms Jiangsu shengdi Medicine Co Ltd 2014-10-17 Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Glioma; Fallopian Tube Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Liver Diseases; Solid tumours; Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Thyroid Neoplasms Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Esophageal Squamous Cell Carcinoma; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Bile Duct Diseases; Thyroid Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Osteoma; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leiomyosarcoma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma Details
Vandetanib AZD-6474; CH-331; ZD-6474 Approved Astrazeneca Pharmaceutical Co Ltd Zactima, Caprelsa Japan Medullary thyroid cancer (MTC) Astrazeneca Pharmaceutical Co Ltd 2011-04-06 Lymphoma; Prostatic Neoplasms; Urethral Neoplasms; Neuroblastoma; Colorectal Neoplasms; Gliosarcoma; Peritoneal Neoplasms; Ureteral Neoplasms; Bile Duct Neoplasms; Lymphoproliferative Disorders; Diffuse Intrinsic Pontine Glioma; Astrocytoma; Gastrointestinal Stromal Tumors; Lung Neoplasms; Thyroid Neoplasms; Pleural Effusion; Glioma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Carcinoma, Neuroendocrine; Multiple Endocrine Neoplasia Type 2b; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Precancerous Conditions; Neoplasm Metastasis; Carcinoma, Hepatocellular; Paraganglioma; von Hippel-Lindau Disease; Anus Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Abdominal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rectal Neoplasms; Pheochromocytoma; Solid tumours; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc Nexavar, 多吉美 EU Thyroid Neoplasms Bayer AG 2005-12-01 Liver Neoplasms; Leukemia, Myeloid; Lymphoma, B-Cell, Marginal Zone; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Fibromatosis, Aggressive; Leiomyosarcoma; Kidney Neoplasms; Leukemia, Erythroblastic, Acute; Solid tumours; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Recurrence; Carcinoma, Renal Cell; Esophageal Neoplasms; Vipoma; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Hemangiosarcoma; Carcinoid Tumor; Carcinoma; Insulinoma; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Multiple Endocrine Neoplasia Type 2a; Hypertension, Portal; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Wilms Tumor; Leukemia, Myelomonocytic, Chronic; Lymphoma, Large-Cell, Immunoblastic; S Details
Axitinib AG-013736; CLS-AX; AG-13736; PF-01367866 Approved Pfizer Pharmaceuticals Ltd (China) Inlyta, 英立达 Mainland China Carcinoma, Renal Cell Pfizer Europe Ma Eeig 2012-01-27 Lymphoma; Carcinoma, Adenoid Cystic; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Sarcoma; Colorectal Neoplasms; Hepatic Insufficiency; Carcinoma, Pancreatic Ductal; Thyroid Neoplasms; Carcinoma, Ductal; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Hepatocellular; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Macular Degeneration; Adrenal Cortex Neoplasms; Kidney Neoplasms; Carcinoid Tumor; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Solid tumours; Glioblastoma; Pancreatic Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Neuroendocrine Tumors; Mesothelioma Details
Fruquintinib HMPL-013 Approved Hutchison Medipharma Ltd 爱优特, Elunate Macau Colorectal Neoplasms Hutchison Medipharma Ltd 2018-09-04 Kidney Diseases; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Sarcoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Solid tumours; Colonic Neoplasms; Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Peritoneal Neoplasms; Lymphoma; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Thyroid Neoplasms; Gastrointestinal Stromal Tumors; Gliosarcoma; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Uterine Cervical Diseases; Choriocarcinoma; Colorectal Neoplasms; Neuroblastoma; Osteosarcoma; Gastrinoma; Psoriasis; Brain Neoplasms; Urethral Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); von Hippel-Lindau Disease; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Paraganglioma; Thyroid Cancer, Papillary; Neoplasm Metastasis; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Prostatic Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Glioma; Germinoma; Carcinoma, Neuroendocrine; Carcinoma, Embryonal; Carcinoma, Squamous Cell; Telangiectasia, Hereditary Hemorrhagic; Thyroid Carcinoma, Anaplastic; Neoplasms; Carcinoid Tumor; Herpes Genitalis; Pheoc Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt Approved Pfizer Pharmaceuticals Ltd (China) 索坦, Sutent Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Teratoma; Ovarian Neoplasms; Fibromatosis, Aggressive; Solid tumours; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Leiomyosarcoma; Fibrosarcoma; HIV Infections; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell, Peripheral; Ependymoma; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangioblastoma; Carcinoma, Islet Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Leukemia, Hairy Cell; Abdominal Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Pelvic Neoplasms; Pheochromocytoma; Glioblastoma; Neurofibromatoses; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Neoplasms; I Details
Ramucirumab IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 Approved Dyax Pharma Cyramza Mainland China Carcinoma, Hepatocellular Lilly Suzhou Pharmaceutical Co Ltd 2014-04-21 Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Klatskin Tumor; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Liver Neoplasms Details
Ripretinib DCC-2618 Approved Deciphera 擎乐, Qinlock United Kingdom Gastrointestinal Stromal Tumors Deciphera Pharmaceuticals Llc 2020-05-15 Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors Details
Tivozanib AV-951; KRN-951; ASP-4130; Kil-8951 Approved Kyowa Hakko Kirin Co Ltd Fotivda United States Carcinoma, Renal Cell Aveo Pharmaceuticals Inc 2017-08-24 Cholangiocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Liver Neoplasms; Sarcoma; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours; Ovarian Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
VEGFR-1/2 peptide vaccine (Keio University) Phase 2 Clinical Keio University Neurofibromatoses; Brain Neoplasms; Glioma Details
PZ-1 PZ-1 Phase 1 Clinical Chongqing University Of Arts And Sciences Solid tumours Details
Pamufetinib TAS-115 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Neoplasms Details
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) Phase 1 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AVI-3207 AVI-3207 Phase 1 Clinical Avixgen Macular Degeneration Details
VEGFR2 peptide vaccine (Tokyo University) Phase 1 Clinical University Of Tokyo Pancreatic Neoplasms Details
Sorafenib Tosylate/MG-K10 MG-D-1609 Phase 2 Clinical Solid tumours Details
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) BC-001 Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd Solid tumours Details
FNX-006 FNX-006 Phase 1 Clinical Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd Triple Negative Breast Neoplasms; Melanoma Details
SYHA-1817 SYHA-1817 Phase 1 Clinical CSPC Pharmaceutical Group Ltd Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell Details
Ilorasertib ABT-348; A-9686600; Abbott-968660 Abbvie Inc Details
R-1530 RG1530; R-1530; RG-1530 F. Hoffmann-La Roche Ltd Details
PF-337210 PF-337210; PF-00337210 Pfizer Inc Details
LM-061 LM-061 Phase 1 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Solid tumours Details
Gersizangitide AXT-107 AsclepiX Therapeutics Inc Details
Gentuximab Genescience Pharmaceuticals Co Ltd Details
AG-13958 AG-13958; AG-013958 Pfizer Inc Details
ODM-203 ODM-203 Orion Corp Details
Simmitinib hydrochloride SOMCL-15-290 Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
Tafetinib Malate SIM-0702; SIM-1005; SIM-010603 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd Neoplasms Details
Ramucirumab biosimilar (Henlius) HLX-12 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd Solid tumours Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
MSB-0254 MSB-0254 Phase 1 Clinical Mabspace Biomedicine (Suzhou) Co Ltd Solid tumours Details
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) Phase 3 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pulocimab AK-109 Phase 2 Clinical Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
VEGFR2 peptide vaccine (VAXIMM) VXM-01 Phase 2 Clinical Merck Serono Glioblastoma; Pancreatic Neoplasms; Colorectal Neoplasms Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
RA1115-B1 RA1115-B1 Phase 1 Clinical Wet Macular Degeneration; Macular Degeneration Details
CEP-11981 ESK-981; CEP-11981; SSR-106462; BOL-303213X Phase 2 Clinical Sanofi Neoplasms; Prostatic Neoplasms Details
Glesatinib 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265; MG-90265X; MGCD-265 Phase 2 Clinical Mirati Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
KDR2-2 Phase 2 Clinical Guangzhou Huiborui Biomedical Technology Co Ltd Glaucoma, Neovascular; Neovascularization, Pathologic; Corneal Neovascularization Details
Cediranib AZD2171; AZD-2171; NSC-732208 Phase 3 Clinical Astrazeneca Plc Ovarian Neoplasms; Solid tumours; Ependymoma; Biliary Tract Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Leukemia; Leiomyosarcoma; Solitary Fibrous Tumor, Pleural; Medulloblastoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoma; Stomach Neoplasms; Rhabdoid Tumor; Spinal Cord Neoplasms; Cystadenocarcinoma, Mucinous; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Cystadenoma, Serous; Glioblastoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Hodgkin Disease; Hypopharyngeal Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Salivary Gland Neoplasms; Carcinoma, Verrucous; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Oligodendroglioma; Ascites; Uveal mel Details
JY-025 JY-025 Phase 3 Clinical Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BR-55 BR-55; BR55 CEUS Phase 2 Clinical Sonus Pharmaceuticals Ltd Ovarian Neoplasms; Neoplasms; Contrast agents; Inflammation; Diagnostic agents Details
KC1036 KC1036; KC-1036 Phase 2 Clinical Beijing Konruns Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Digestive System Neoplasms; Neoplasm Metastasis Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Cholangiocarcinoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Nasopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Neoplasms; Carcinoma, Renal Cell; Solid tumours; Biliary Tract Neoplasms Details
Sitravatinib IND-155305; MG-516; MG-91516; MGCD-516 Phase 3 Clinical Mirati Therapeutics Inc Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Carcinoma, Squamous Cell; Mouth Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Hepatic Insufficiency; Ureteral Neoplasms; Kidney Neoplasms; Liposarcoma; Lung Diseases; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details
Olinvacimab SSS-23; TTAC-0001 Phase 2 Clinical Pharmabcine Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis Details
Brivanib Alaninate ZL-2301; BMS-540215; BMS-582664 Phase 2 Clinical Bristol-Myers Squibb Company Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Adenocarcinoma; Endometrial Neoplasms; Liver Neoplasms; Colorectal Neoplasms; Sarcoma; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Solid tumours Details
Telatinib EOC-315; BAY-57-9352 Phase 2 Clinical Bayer AG Solid tumours; Stomach Neoplasms Details
EDP317 ACTB-1003; EOC-317; EDP-317 Phase 1 Clinical Bayer AG, Act Biotech Inc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap